NCT05264025RecruitingPhase 1/2
Fexofenadine in Patients With Active Rheumatoid Arthritis
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid
Source: ClinicalTrials.gov · Last updated 31 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 10 Jan 2022
- Start date
- 1 Jun 2022
- Primary completion date
- Dec 2025
- Lead sponsor
- October 6 University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05264025
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 80
- From 1 Jun 2022 to the primary completion date, Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any changes in using medication (changing the dosage or type of medicines
- Receive hormone replacement therapy, warfarin, and other anticoagulants
Other illness
- History of biological DMARDS.
- History/presence of acute heart disease, liver and kidney diseases, COPD
- Intolerance or allergy to fexofenadine or methotrexate
Other
- Alcohol abuse
Who the study is looking for
- Moderate to severe RA (disease activity score-28 joints: DAS-28 \> 3.2) were recruited.
- Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
- Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beni suef hospital Coordinator of this site? Confirm its status | Banī Suwayf | Egypt | Recruiting |
| Faculty of Medicine - Beni Suef Hospital Coordinator of this site? Confirm its status | Banī Suwayf | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.